Tag:
Pharmacyclics
Latest Headlines
Latest Headlines
Pharmacyclics impresses (again) with improved leukemia data on blockbuster hopeful
Anyone looking for a solid reason why J&J's Janssen would pay $150 million upfront to partner on Pharmacyclics' experimental blood cancer drug need look no further than the leukemia data the
J&J nabs Pharmacyclics cancer candidate in $975M deal
Johnson & Johnson's ( $JNJ ) Janssen Biotech unit has made a big deal with the small biotech Pharmacyclics. Janssen will pay $150 million up front--and $975 million total, if milestones are
Updated: J&J locks in blood cancer compound in $975M pact
A unit of Johnson & Johnson ( $JNJ ) has made big bet on the future of developer Pharmacyclics' ( $PCYC ) experimental compound in midstage testing for blood cancers, shelling out $150 million in
Pharmacyclics snares $39.5M development deal
Sunnyvale, CA-based Pharmacyclics has scored a $39.5 million development deal with France's Servier. The developer gets $11 million upfront and $4 million to support its research work over 24 months.
